Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Armocibart in Hemophilia B: NCT06312475 Clinical Landscape Report 2026
9 min read
Armocibart in Hemophilia B: NCT06312475 Clinical Landscape Report 2026
18 September 2026
NCT06312475 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Deramiocel in Cardiomyopathies: NCT06304064 Clinical Landscape Report 2026
9 min read
Deramiocel in Cardiomyopathies: NCT06304064 Clinical Landscape Report 2026
18 September 2026
NCT06304064 clinical landscape for Cardiomyopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
SPK-8011 in Hemophilia A: NCT06297486 Clinical Landscape Report 2026
9 min read
SPK-8011 in Hemophilia A: NCT06297486 Clinical Landscape Report 2026
18 September 2026
NCT06297486 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Emicizumab in Hemophilia A: NCT06320626 Clinical Landscape Report 2026
9 min read
Emicizumab in Hemophilia A: NCT06320626 Clinical Landscape Report 2026
18 September 2026
NCT06320626 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Tranexamic Acid in Hemorrhage: NCT06345833 Clinical Landscape Report 2026
9 min read
Tranexamic Acid in Hemorrhage: NCT06345833 Clinical Landscape Report 2026
18 September 2026
NCT06345833 clinical landscape for Hemorrhage: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
SR-604 in Hemophilia B: NCT06349473 Clinical Landscape Report 2026
9 min read
SR-604 in Hemophilia B: NCT06349473 Clinical Landscape Report 2026
18 September 2026
NCT06349473 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
EN-001 (Encell) in Muscular Dystrophy, Duchenne: NCT06328725 Clinical Landscape Report 2026
9 min read
EN-001 (Encell) in Muscular Dystrophy, Duchenne: NCT06328725 Clinical Landscape Report 2026
18 September 2026
NCT06328725 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
LNP-1265/REGV-131 in Hemophilia B: NCT06379789 Clinical Landscape Report 2026
9 min read
LNP-1265/REGV-131 in Hemophilia B: NCT06379789 Clinical Landscape Report 2026
18 September 2026
NCT06379789 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Motixafortide in Acute Chest Syndrome: NCT06506461 Clinical Landscape Report 2026
9 min read
Motixafortide in Acute Chest Syndrome: NCT06506461 Clinical Landscape Report 2026
18 September 2026
NCT06506461 clinical landscape for Acute Chest Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
GEN-6050X in Muscular Dystrophy, Duchenne: NCT06392724 Clinical Landscape Report 2026
9 min read
GEN-6050X in Muscular Dystrophy, Duchenne: NCT06392724 Clinical Landscape Report 2026
18 September 2026
NCT06392724 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Albutrepenonacog alfa in Hemophilia B: NCT06399289 Clinical Landscape Report 2026
9 min read
Albutrepenonacog alfa in Hemophilia B: NCT06399289 Clinical Landscape Report 2026
18 September 2026
NCT06399289 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Captopril in Muscular Dystrophy, Duchenne: NCT06485661 Clinical Landscape Report 2026
9 min read
Captopril in Muscular Dystrophy, Duchenne: NCT06485661 Clinical Landscape Report 2026
18 September 2026
NCT06485661 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →